Modulating pro-fibrotic macrophages using yeast beta-glucan microparticles prepared by Pressurized Gas eXpanded

S Naiel1, N Dowdall2, Q Zhou3

  • 1Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, 50 Charlton Avenue East, L314-5, Hamilton, ON, L8N 4A6, Canada.

Biomaterials
|September 9, 2024
PubMed

Insights

Yeast beta-glucan (YBG) microparticles processed with new technology show promise for treating lung fibrosis. These microparticles effectively reprogram pro-fibrotic macrophages into anti-fibrotic ones, offering a potential therapeutic strategy.

Area of Science:

  • Immunology
  • Biomaterials Science
  • Pulmonary Medicine

Background:

  • Pro-fibrotic M2-like macrophages drive lung fibrosis through growth factor and cytokine production.
  • Yeast beta-glucan (YBG) microparticles can modulate macrophage polarization via Dectin-1 receptor engagement.
  • Current YBG microparticle fabrication methods yield unpredictable immunomodulatory outcomes.

Purpose of the Study:

  • To develop YBG microparticles with enhanced properties for improved immunomodulation.
  • To investigate the efficacy of PGX-YBG microparticles in modulating macrophage polarization.
  • To assess the therapeutic potential of PGX-YBG for lung fibrotic diseases.

Main Methods:

  • Fabrication of YBG microparticles using Pressurized Gas eXpanded liquids (PGX) Technology.
  • Characterization of PGX-YBG microparticles (surface area, density, size distribution).
  • In vitro and ex vivo assessment of macrophage polarization and Dectin-1/TLR activation.

Main Results:

  • PGX-YBG microparticles exhibited higher surface areas, lower densities, and more uniform size distributions than spray-dried YBGs.
  • PGX-YBG demonstrated more efficient Dectin-1 activation with minimal TLR 2/4 activation in vitro.
  • PGX-YBG effectively converted M2-like fibrotic macrophages to a fibrosis-suppressing phenotype in vitro and ex vivo.

Conclusions:

  • PGX Technology enables the fabrication of YBG microparticles with superior physicochemical and immunomodulatory properties.
  • PGX-YBG microparticles represent a promising therapeutic agent for lung fibrosis by reprogramming pro-fibrotic macrophages.
  • This approach holds potential for treating diverse fibrotic lung diseases.

Related Concept Videos

Microbes in Food Production01:29

Microbes in Food Production

Microbial fermentation is central to food biotechnology, enhancing flavor, texture, preservation, and stability. Fermentative microorganisms metabolize carbohydrates into organic acids, alcohols, and other metabolites that inhibit spoilage organisms and improve digestibility while contributing distinctive sensory qualities.In baking, amylases naturally present in flour hydrolyze starch into monosaccharides such as glucose, which Saccharomyces cerevisiae ferments anaerobically. Through...
Bioreactor Controls-III01:22

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Production of Organic Acids01:25

Production of Organic Acids

Lactic acid, an important organic acid extensively applied in food, pharmaceutical, and biodegradable polymer industries, is primarily produced via microbial fermentation. This method is favored over chemical synthesis due to its environmental sustainability and capacity for enantiomerically pure product formation. Among various microbial processes, the fermentation of starch-based substrates stands out due to the abundance and renewability of raw materials like corn and potatoes.Hydrolysis of...